NBC Los Angeles

FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.

The weekly injection is now the first drug treatment option cleared for patients with obesity and moderate-to-severe obstructive sleep apnea, or OSA, which refers to breathing interrupted during sleep ...
Hosted on MSN

Zepbound vs. Wegovy: Which obesity treatment might be right for you?

Theres no question that medications like semaglutide (Wegovy) and tirzepatide (Zepbound) make headlines. Theyre two of the handful of medications approved specifically for weight loss. While both can ...
Nasdaq

Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients

INDIANAPOLIS, Feb. 25, 2025 /PRNewswire/ -- Today Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new ...
Seeking Alpha

LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound

Walmart (WMT), with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials Strategic collaboration marks the first time ...
Morningstar

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or ...

At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance (PASI 100) and ≥10% weight loss In ...